SCHEMBL1103260

SCHEMBL1103260

Cc1ccc(-c2c3ccccc3c(-c3ccc(C)cc3)c3c2cnc2ccccc23)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.48
NPSR1 Q6W5P4 3/20 0.48
ALDH1A1 P00352 3/20 0.48
MAPT P10636 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
GRM5 P41594 2/20 0.47
CYP1A1 P04798 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP1B1 Q16678 1/20 0.42
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
XBP1 P17861 1/20 0.40
ATM Q13315 1/20 0.40
KDM4E B2RXH2 2/20 0.40
ACHE P22303 1/20 0.40
ADORA2A P29274 1/20 0.40
HPGD P15428 1/20 0.39
CDK4 P11802 1/20 0.39
CCND1 P24385 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103411 0.97 ALDH1A1 (0.52) HTTNPSR1ALDH1A1MAPTSMN1; SMN2
SCHEMBL1103531 0.89 ALDH1A1 (0.42) HTTNPSR1ALDH1A1MAPTSMN1; SMN2
SCHEMBL1103262 0.89 SSTR2 (0.42) HTTNPSR1ALDH1A1MAPTSMN1; SMN2
SCHEMBL1103449 0.88 ESR1 (0.42) HTTNPSR1ALDH1A1MAPTSMN1; SMN2
SCHEMBL1103486 0.88 ESR1 (0.42) HTTNPSR1ALDH1A1MAPTSMN1; SMN2
SCHEMBL1103479 0.88 ESR1 (0.42) HTTNPSR1ALDH1A1MAPTSMN1; SMN2
SCHEMBL1103400 0.88 ALDH1A1 (0.47) HTTNPSR1ALDH1A1MAPTSMN1; SMN2
SCHEMBL1103301 0.87 ESR1 (0.41) HTTNPSR1ALDH1A1MAPTSMN1; SMN2
SCHEMBL1103249 0.87 ESR1 (0.41) HTTNPSR1ALDH1A1MAPTSMN1; SMN2
SCHEMBL1103380 0.87 ESR1 (0.41) HTTNPSR1ALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 HTT 4390/4885NPSR1 4037/4885ALDH1A1 1015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.